Introduction: This systematic review addresses the use of epidermal growth factor receptor
(egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients …

Background Both first and second-generation EGFR-TKIs are recommended in advanced
NSCLC with common EGFR mutations. However, there are few data on the difference in …

Background In the first line treatment of non-small cell lung cancer (NSCLC), several clinical
trials have shown that not all NSCLC patients can benefit from treatment with tyrosine kinase …

Background It remains unknown which is the optimal first-line treatment regimen for patients
with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer …

An ideal target-based agent for the treatment of cancer patients should fulfil a number of
requirements, including the availability of biomarkers to select the target population …

Background: First-line treatments for nonsmall cell lung cancer (NSCLC) harboring
epidermal growth factor receptor (EGFR) mutations have been evaluated in various clinical …

Background Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy
is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring …

背景与目的 表皮因子受体酪氨酸激酶抑制剂 (epidermal growth factor receptor tyrosine kinase
inhibitor, EGFR-TKI) 应用于非小细胞肺癌 (non-small cell lung cancer, NSCLC) …

Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …

Background: Treatment options for EGFR mutant advanced/metastatic NSCLC patients
continue to evolve with the development of 2nd and 3rd generation EGFR TKIs. We aim to …